New laser aims to sharpen vision for the farsighted
NCT ID NCT05264623
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the safety and effectiveness of the TENEO 317 excimer laser used in LASIK surgery to treat farsightedness (hyperopia) with or without astigmatism. About 140 adults aged 22 and older will receive the laser treatment in one or both eyes and be followed for 12 months. The main goals are to see if vision improves to 20/40 or better without glasses and if the prescription correction is accurate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TENEO 317 Model 2 excimer laser (device)
What this could lead to
If successful, this laser could offer a safe and effective option for LASIK surgery to correct farsightedness and astigmatism.
What could go wrong
This is a single-arm, non-randomized study with no comparison group, so results may not apply broadly. Risks include typical LASIK complications like dry eyes or vision issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPEROPIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 101
Bloomington, Minnesota, 55420, United States
-
Site 102
Amherst, New York, 14228, United States
-
Site 103
Omaha, Nebraska, 68118, United States
-
Site 104
Saint Louis Park, Minnesota, 55416, United States
-
Site 106
Cedar Park, Texas, 78613, United States
-
Site 108
Sioux Falls, South Dakota, 57108, United States
-
Site 111
Fort Myers, Florida, 33912, United States
-
Site 112
Pittsburgh, Pennsylvania, 15213, United States
-
Site 113
Newport Beach, California, 92660, United States